The Pharmacoeconomic Burden of Insomnia: Current Treatment Challenges and Updates on Safe and Efficacious Options

The Pharmacoeconomic Burden of Insomnia: Current Treatment Challenges and Updates on Safe and Efficacious Options

Faculty Presenters

Douglas S. Burgoyne, PharmD, FAMCP
Associate Adjunct Professor
Department of Pharmacotherapy
University of Utah College of Pharmacy
Salt Lake City, Utah

Julie A. Dopheide, PharmD, BCPP, FASHP
Professor of Clinical Pharmacy
University of Southern California School of Pharmacy and Keck School of Medicine
Los Angeles, California
 
Program Description
In 2014, the classification of insomnia as a comorbid designation was revised, and it is now considered a disorder defined as difficulty with the initiation or maintenance of sleep. About 1 in 5 cases of insomnia becomes chronic and can persist for years, making the economic and quality of life burdens of insomnia significant, especially on vulnerable patient groups and those with coexisting medical or psychiatric disorders. Managed care professionals must converse with clinicians to improve knowledge and use of guideline recommendations and the role of cognitive behavioral therapy for insomnia (CBT-I) in clinical practice. Likewise, pharmacists involved in the treatment and management of patients with insomnia must accurately explain the risks and benefits of currently available insomnia drugs as well as emerging treatment approaches. The up-to-date information explored in this program will help managed care professionals incorporate costeffective pharmaceutical care and protocols into practice to provide high-quality care to patients with insomnia.

Target audience: Specialty and managed care pharmacists, managed care payers, pharmacy directors, pharmacy benefit managers, specialty pharmacy directors, and any other pharmacist and/or healthcare professional interested in or involved in the care of patients with insomnia.
Type of activity: Application
Release date: November 3, 2020
Expiration date: November 3, 2021
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Characterize the pathophysiology, epidemiology, and disease burden of insomnia including the impact on quality of life in vulnerable patient groups
• Identify appropriate pharmacotherapy for insomnia based on guideline recommendations, drug efficacy and safety profiles, and patient factors
• Examine the economic burden of insomnia and impact of available treatment options, including effects on vulnerable patient groups

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-330-H01-P. The activity is available for CE credit through November 3, 2021.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures
Douglas S. Burgoyne, PharmD, FAMCP, and Julie A. Dopheide, PharmD, BCPP, FASHP, have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms